$1.30
7.44% yesterday
Nasdaq, Nov 25, 09:50 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Century Therapeutics Inc Classifications & Recommendation:

Buy
86%
Hold
14%

Century Therapeutics Inc Price Target

Target Price $8.67
Price $1.30
Potential
Number of Estimates 6
6 Analysts have issued a price target Century Therapeutics Inc 2025 . The average Century Therapeutics Inc target price is $8.67. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Century Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Century Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Century Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 2.24 3.16
56.92% 40.94%
EBITDA Margin -5,006.25% -3,995.07%
128.84% 20.20%
Net Margin -8,703.04% -3,892.82%
135.21% 55.27%

7 Analysts have issued a sales forecast Century Therapeutics Inc 2024 . The average Century Therapeutics Inc sales estimate is

$3.2m
Unlock
. This is
17.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.4m 63.57%
Unlock
, the lowest is
$2.4m 10.78%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $2.2m 56.92%
2024
$3.2m 40.94%
Unlock
2025
$3.2m 2.26%
Unlock
2026
$4.0m 23.89%
Unlock
2027
$23.2m 480.00%
Unlock
2028
$155m 565.95%
Unlock

1 Analyst has issued an EBITDA forecast Century Therapeutics Inc 2024 . The average Century Therapeutics Inc EBITDA estimate is

$-126m
Unlock
. This is
5.96% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-126m 5.96%
Unlock
, the lowest is
$-126m 5.96%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-112m 1.42%
2024
$-126m 12.48%
Unlock
2025
$-141m 11.88%
Unlock

EBITDA Margin

2023 -5,006.25% 128.84%
2024
-3,995.07% 20.20%
Unlock
2025
-4,370.93% 9.41%
Unlock

1 Analyst has issued a net profit forecast Century Therapeutics Inc 2024 . The average Century Therapeutics Inc net profit estimate is

$-123m
Unlock
. This is
22.04% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-123m 22.04%
Unlock
, the lowest is
$-123m 22.04%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-195m 1.32%
2024
$-123m 36.96%
Unlock
2025
$-138m 12.42%
Unlock

Net Margin

2023 -8,703.04% 135.21%
2024
-3,892.82% 55.27%
Unlock
2025
-4,279.26% 9.93%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share $ -2.30 -1.45
1.32% 36.96%
P/E negative
EV/Sales negative

1 Analysts have issued a Century Therapeutics Inc forecast for earnings per share. The average Century Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.45
Unlock
. This is
22.04% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.45 22.04%
Unlock
, the lowest is
$-1.45 22.04%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.30 1.32%
2024
$-1.45 36.96%
Unlock
2025
$-1.63 12.41%
Unlock

P/E ratio

Current -0.70 2.94%
2024
-0.90 28.57%
Unlock
2025
-0.80 11.11%
Unlock

Based on analysts' sales estimates for 2024, the Century Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-10.44
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
35.01
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -12.26 6.84%
2024
-10.44 14.82%
Unlock
2025
-10.21 2.21%
Unlock
2026
-8.24 19.29%
Unlock
2027
-1.42 82.76%
Unlock
2028
-0.21 84.98%
Unlock

P/S ratio

Current 41.09 14.77%
2024
35.01 14.80%
Unlock
2025
34.24 2.21%
Unlock
2026
27.64 19.29%
Unlock
2027
4.76 82.76%
Unlock
2028
0.72 84.98%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today